drugset / Trial / NCT06212154
CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy
Phase 1
Unknown
13 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Suzhou Fundamenta Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
To Evaluate the Safety and Efficacy of ThisCART19A for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy
Timeline
- Start
- 2024-01-20
- Primary completion
- 2024-12-31
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ThisCART19A | Cell therapy | — | Other |